ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1577

Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life

Sarah Mann1, Aamir Hussain2, Anisha Dua3, Angelina Patrone4, Kalen Larson5, Peter Merkel6 and Robert Micheletti7, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Department of Dermatology, Georgetown University, Washington, DC, 3Northwestern University, Chicago, IL, 4Patient Partner, Philadelphia, PA, 5Vasculitis Foundation, Kansas City, MO, 6University of Pennsylvania, Philadelphia, PA, 7Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2022

Keywords: Cutaneous, quality of life, skin, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Cutaneous manifestations of vasculitis can cause pruritus, pain, and ulceration, and their psychosocial impacts may be significant. However, the quality-of-life (QoL) impact of skin vasculitis has not been systematically evaluated. This study aimed to assess the QoL of patients with cutaneous manifestations of vasculitis and to determine potential factors affecting patients’ experiences.

Methods: Utilizing the Vasculitis Patient-Powered Research Network (VPPRN), and incorporating feedback from patient research partners, an online survey was disseminated to patients with cutaneous manifestations of vasculitis (all major types), including validated measures of skin-related QoL (Skindex-29) and general health and wellbeing (SF-36). Skindex-29 results were categorized using previously published methods, and SF-36 scores of 50 on a scale of 0-100 were considered “average.”

Results: A total of 234 responses were received. After eliminating duplicates and incomplete responses, 190 remained. Of these, 107 patients with any of several forms of vasculitis had experienced active skin lesions within the preceding four weeks and were included for analysis. The mean QoL impact of skin vasculitis was considered at least moderately impaired (and, frequently, very severely impaired) in every domain of the Skindex-29, including “symptoms,” “emotions,” “functioning,” and “overall” (Figure 1). QoL was below average in six out of the eight domains of the SF-36 health survey (Figure 2). QoL impact was greater with increasing disease severity. Analyzed by vasculitis type, cutaneous small vessel vasculitis (CSVV) had an impact on QoL which met or exceeded that of other vasculitis subtypes, as assessed by both the Skindex-29 and the SF-36. QoL impact was greatest for those with disease duration of less than 2 years.

Conclusion: Cutaneous manifestations of vasculitis are associated with diminished QoL across multiple domains, suggesting skin vasculitis has a significant impact on health, wellbeing, patient symptoms, and self-perception of health. These data may help clinicians be more aware of the impact of skin disease in vasculitis and may form the basis of a patient-reported outcome tool for measuring disease severity and response to treatment in clinical studies. Future work will evaluate changes in QoL resulting from successful management of cutaneous vasculitis.

Supporting image 1

Supporting image 2


Disclosures: S. Mann, None; A. Hussain, None; A. Dua, None; A. Patrone, None; K. Larson, None; P. Merkel, AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Neutrolis, Takeda, CSL Behring, Dynacure, EMDSerono, Immagene, Jannsen, Kiniksa, Magenta, Novartis, Pfizer, Q32, Regeneron, Sparrow, Eicos, Electra, Kyverna, UpToDate; R. Micheletti, Vertex, Celgene, Pfizer, Chemocentryx, Cabaletta Bio.

To cite this abstract in AMA style:

Mann S, Hussain A, Dua A, Patrone A, Larson K, Merkel P, Micheletti R. Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-cutaneous-vasculitis-on-health-related-quality-of-life/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-cutaneous-vasculitis-on-health-related-quality-of-life/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology